Clearmind Medicine hits primary safety endpoint in Phase I/IIa alcohol use disorder trial
Clearmind Medicine (NASDAQ:CMND), a clinical-stage pharmaceutical company focused on developing novel psychedelic-derived therapies, announced today that its lead candidate, CMND-100, has successfully met the primary safety and tolerability endpoints in its Phase I/IIa clinical trial.










